These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38504824)

  • 21. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Self-Adjuvanted, Modular, Antigenic VLP for Rapid Response to Influenza Virus Variability.
    Sharma J; Shepardson K; Johns LL; Wellham J; Avera J; Schwarz B; Rynda-Apple A; Douglas T
    ACS Appl Mater Interfaces; 2020 Apr; 12(16):18211-18224. PubMed ID: 32233444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
    Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
    Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.
    Alpuche-Lazcano SP; Stuible M; Akache B; Tran A; Kelly J; Hrapovic S; Robotham A; Haqqani A; Star A; Renner TM; Blouin J; Maltais JS; Cass B; Cui K; Cho JY; Wang X; Zoubchenok D; Dudani R; Duque D; McCluskie MJ; Durocher Y
    Commun Med (Lond); 2023 Aug; 3(1):116. PubMed ID: 37612423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Bacterial Expression Systems Based on Potato Virus Y-like Particles for Vaccine Generation.
    Ogrina A; Skrastina D; Balke I; Kalnciema I; Jansons J; Bachmann MF; Zeltins A
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines.
    Setyo Utomo DI; Suhaimi H; Muhammad Azami NA; Azmi F; Mohd Amin MCI; Xu J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers.
    Cohen AA; Yang Z; Gnanapragasam PNP; Ou S; Dam KA; Wang H; Bjorkman PJ
    PLoS One; 2021; 16(3):e0247963. PubMed ID: 33661993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
    Lindsay BJ; Bonar MM; Costas-Cancelas IN; Hunt K; Makarkov AI; Chierzi S; Krawczyk CM; Landry N; Ward BJ; Rouiller I
    Vaccine; 2018 Apr; 36(16):2147-2154. PubMed ID: 29550194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone.
    Zhang B; Chao CW; Tsybovsky Y; Abiona OM; Hutchinson GB; Moliva JI; Olia AS; Pegu A; Phung E; Stewart-Jones G; Verardi R; Wang L; Wang S; Werner A; Yang ES; Yap C; Zhou T; Mascola JR; Sullivan NJ; Graham BS; Corbett KS; Kwong PD
    bioRxiv; 2020 Aug; ():. PubMed ID: 32676596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
    Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VLP-factory™ and ADDomer
    Sari-Ak D; Bufton J; Gupta K; Garzoni F; Fitzgerald D; Schaffitzel C; Berger I
    Curr Protoc; 2021 Mar; 1(3):e55. PubMed ID: 33729713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    Microbiol Spectr; 2024 Aug; 12(8):e0095924. PubMed ID: 38916311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy.
    Wei J; Li Z; Yang Y; Ma X; An W; Ma G; Su Z; Zhang S
    Vaccine; 2020 Aug; 38(38):5987-5996. PubMed ID: 32713681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.
    Brune KD; Leneghan DB; Brian IJ; Ishizuka AS; Bachmann MF; Draper SJ; Biswas S; Howarth M
    Sci Rep; 2016 Jan; 6():19234. PubMed ID: 26781591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S2 Peptide-Conjugated SARS-CoV-2 Virus-like Particles Provide Broad Protection against SARS-CoV-2 Variants of Concern.
    Heo CK; Lim WH; Moon KB; Yang J; Kim SJ; Kim HS; Kim DJ; Cho EW
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
    Shen H; Xue C; Lv L; Wang W; Liu Q; Liu K; Chen X; Zheng J; Li X; Cao Y
    Virus Res; 2013 Dec; 178(2):430-6. PubMed ID: 24050994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.